AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rocket Pharmaceuticals investors face August 11, 2025 lead plaintiff deadline.
ByAinvest
Sunday, Jul 13, 2025 11:26 am ET1min read
Rosen Law Firm reminds investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the August 11, 2025 lead plaintiff deadline for a class action lawsuit. Investors may be entitled to compensation without payment of fees or costs through a contingency fee arrangement. To join the lawsuit, visit https://rosenlegal.com/submit-form/?case_id=40316 or call Phillip Kim, Esq., at 866-767-3653.
Investors who purchased Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025, and May 26, 2025, are reminded of an important August 11, 2025, deadline. The Rosen Law Firm has announced that a class action lawsuit has been filed on behalf of investors who may have suffered losses due to alleged securities fraud during this period.The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements about the safety and clinical trial protocol of its drug, RP-A501. Specifically, the complaint claims that the company knew about Serious Adverse Events (SAEs), including the death of participants, but did not disclose this information to shareholders. This led to artificially inflated stock prices, resulting in damages when the true details were revealed.
Investors who purchased securities during the Class Period may be entitled to compensation without paying any out-of-pocket fees or costs through a contingency fee arrangement. To join the Rocket Pharmaceuticals class action, investors should visit [https://rosenlegal.com/submit-form/?case_id=40316](https://rosenlegal.com/submit-form/?case_id=40316) or contact Phillip Kim, Esq., at 866-767-3653.
The Rosen Law Firm, with a strong track record in securities class actions, encourages investors to select qualified counsel. The firm has achieved significant settlements in the past and is ranked highly by ISS Securities Class Action Services.
Investors should act promptly, as the August 11 deadline is approaching. Failure to do so may result in missing out on potential compensation.
References:
[1] https://www.prnewswire.com/news-releases/rckt-investors-have-opportunity-to-lead-rocket-pharmaceuticals-inc-securities-fraud-lawsuit-302503563.html
[2] https://www.marketscreener.com/quote/stock/ROCKET-PHARMACEUTICALS-IN-40561561/news/RCKT-Investors-Have-Opportunity-to-Lead-Rocket-Pharmaceuticals-Inc-Securities-Fraud-Lawsuit-50496023/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet